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RNA Interference Demonstrates a Novel Role for Integrin-Linked
Kinase as a Determinant of Pancreatic Adenocarcinoma Cell
Gemcitabine Chemoresistance
Mark S. Duxbury, Hiromichi Ito, Eric Benoit, Talat Waseem, Stanley W. Ashley, and Edward
E. Whang
Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston,
Massachusetts
Abstract
Integrin-linked kinase (ILK) facilitates signal transduction between extracellular events and
important intracellular survival pathways involving protein kinase B/Akt. We examined the role of
ILK in determining pancreatic adenocarcinoma cellular chemoresistance to the nucleoside analogue
gemcitabine. Cellular ILK expression was quantified by Western blot analysis. We examined the
effects of overexpression of active ILK and of ILK knockdown induced by RNA interference on
gemcitabine chemoresistance. We also examined the effects of modulating ILK expression on
gemcitabine-induced caspase 3– mediated apoptosis, phosphorylation status of Akt (Ser473) and
glycogen synthase kinase. Overexpression of ILK increased cellular gemcitabine chemoresistance,
whereas ILK knockdown induced chemosensitization via increased caspase 3– mediated apoptosis.
ILK knockdown attenuated Akt Ser473 and glycogen synthase kinase phosphorylation, whereas
overexpression of constitutively active myristoylated Akt was sufficient to induce significant
recovery in gemcitabine chemoresistance in the presence of ILK knockdown. Levels of ILK
expression affect gemcitabine chemoresistance in pancreatic adenocarcinoma cells. This novel
finding suggests that therapies directed against ILK and its downstream signaling targets may have
the potential to enhance the efficacy of gemcitabine-based chemotherapy.
Integrin-linked kinase (ILK) is an intracellular serine/threonine kinase that interacts with the
cytoplasmic domains of integrin β1 and β3 subunits (1). This 59-kDa protein contains a
phosphoinositide phospholipid–binding domain, which is flanked by NH2-terminal ankyrin
repeat and COOH-terminal kinase domains. ILK kinase activity is stimulated by cellular
attachment to extracellular matrix components and by growth factors. These stimuli result in
suppression of apoptosis and promotion of cell survival via protein kinase B/Akt signaling
events. ILK seems to couple integrin and growth factor receptors to this important cell survival
pathway. ILK is also able to induce inhibitory phosphorylation of glycogen synthase kinase 3
(GSK-3), which modulates cyclin D1–mediated cell cycle regulation as well as activities of
transcription factors, including activator protein and β-catenin-Lef-1/Tcf (2,3). Cellular
adhesion plays an important role in determining cellular resistance to chemotherapeutic agents
in a range of malignancies (4–8), and evidence strongly implicates integrin signaling in
adhesion-dependent chemoresistance (9–11). Inhibition of ILK using small-molecule
inhibitors and dominant-negative ILK expression constructs has been shown to attenuate the
invasiveness of human tumor cells (12), suggesting that this molecule may be therapeutically
© 2005 American Association for Cancer Research.
Requests for reprints: Edward E. Whang, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis
Street, Boston, MA 02115. Phone: 617-732-8669; Fax: 617-739-1728; E-mail: ewhang1@partners.org.
NIH Public Access
Author Manuscript
Clin Cancer Res. Author manuscript; available in PMC 2009 August 28.
Published in final edited form as:
Clin Cancer Res. 2005 May 1; 11(9): 3433–3438. doi:10.1158/1078-0432.CCR-04-1510.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
relevant. However, despite substantial evidence linking downstream targets of ILK to tumor
cell chemoresistance, the role of ILK in this aspect of malignant cellular behavior has not been
studied.
Pancreatic adenocarcinoma is among the most chemoresistant of malignancies. Even treatment
with the current first line chemotherapeutic agent, the nucleoside analogue gemcitabine (2′,2′-
difluorodeoxycytidine), offers minimal benefit in terms of survival and quality of life (13). Akt
plays a central role in the resistance of pancreatic adenocarcinoma cells to apoptotic stimuli,
including exposure to gemcitabine (14–16). Increased Akt activity protects cells from apoptosis
in a variety of ways, including direct suppression of caspase activation (17,18). Given the
importance of ILK in protein kinase B/Akt signaling, we hypothesized that targeting ILK might
represent a novel approach to modulate the chemoresistance of pancreatic adenocarcinoma
cells to gemcitabine. In this study, we present the first evidence indicating a novel role for ILK
in determining pancreatic adenocarcinoma cellular chemoresistance to gemcitabine.
Materials and Methods
Cells and cell culture
PANC1, MIAPaCa2, and Capan2 pancreatic ductal adenocarcinoma cells were obtained from
American Type Culture Collection (Rockville, MD). Cells were maintained in DMEM
containing 10% fetal bovine serum (Life Technologies, Gaithersburg, MD). Cells were
incubated in a humidified (37°C, 5% CO2) incubator and passaged upon reaching 80%
confluence.
Expression vectors and transfection
Constitutively active ILK [ILK(S343D)], constitutively active myristoylated Akt, and
dominant-negative Akt (K179M) expression constructs were obtained from Upstate (Waltham,
MA). Cells were transfected with the appropriate expression construct, or control empty vector
(pUSE), using Lipofect-AMINE 2000 (Invitrogen, Carlsbad, CA) in accordance with the
manufacturer’s protocol. Stable clones were selected by continuous treatment with G418 (Life
Technologies, 0.8 mg/mL) over 4 weeks.
Small interfering RNA
Small interfering RNA (siRNA) targeting the following sequences were synthesized and
purified by Qiagen-Xeragon (Germantown, MD): ILK sense 5′-
CCUGACGAAGCUCAACGAGAAd(TT)-3′, ILK antisense 5′-
UUCUCGUUGAGCUUCGUCAGGd(TT)-3′; control sense 5′-
CCUGACGAAGCUCAACGAAAAd(TT)-3′, control antisense 5′-
UUUUCGUUGAGCUUCGUCAGGd(TT)-3′. The target specificity of these sequences was
confirmed by BLAST search (http://www.ncbi.nih.gov/BLAST). Homologous siRNAs were
dissolved in buffer [100 mmol/L potassium acetate, 30 nmol/L HEPES-KOH, 2 nmol/L
magnesium acetate (pH 7.4)] to a final concentration of 20 µmol/L, heated to 90°C for 60
seconds and incubated at 37°C for 60 minutes before use to disrupt any higher order aggregates
formed during synthesis. Cells were plated into 35-mm 6-well trays and allowed to adhere for
24 hours. In all, 8 µL siPORT Amine transfection reagent (Ambion, Inc., Austin, TX) per well
were added to serum-free medium for a final complexing volume of 200 µL, vortexed, and
incubated at room temperature for 15 minutes. The transfection reagent/siRNA complexes
were added to the wells containing 800 µL medium with 10% fetal bovine serum and incubated
in normal cell culture conditions for 6 hours, after which 1 mL DMEM containing 10% fetal
bovine serum was added. Assays were done 48 hours post-transfection.
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Cytotoxicity assay
Cytotoxicity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay (MTT, Trevigen, Inc., Gaithersburg, MD) in accordance with the
manufacturer’s instructions. Results of the MTT assay have been shown to correlate well with
[3H]-thymidine incorporation in pancreatic cancer cell lines (19). Logarithmically growing
cells were plated at 5 × 103 cells per well in 96-well plates, allowed to adhere overnight, and
were cultured in the presence or absence of 0 to 10 µmol/L gemcitabine. Gemcitabine-induced
cytotoxicity was determined after 24 hours of exposure. Plates were read using a Vmax
microplate spectrophotometer (Molecular Devices, Sunnyvale, CA) at a wavelength of 570 nm
corrected to 650 nm and normalized to controls. Each independent experiment was done thrice,
with 10 determinations for each condition tested. The concentration of gemcitabine required
to inhibit proliferation by 50% (IC50) was calculated from these results. At identical time points,
cells were trypsinized to form a single cell suspension. Intact cells, determined by trypan blue
exclusion, were counted using a Neubauer hemocytometer (Hausser Scientific, Horsham, PA).
Cell counts were used to confirm MTT results.
Apoptosis staining
Following gemcitabine treatment, cells were washed, resuspended in 0.5 mL of PBS, and 1
µL/mL YO-PRO-1, and propidium iodide were added (Vybrant Apoptosis Assay Kit #4,
Molecular Probes, Eugene, OR). Cells were incubated for 30 minutes on ice and analyzed by
flow cytometry (FACScan, Becton Dickinson, Franklin Lakes, NJ), measuring fluorescence
emission at 530 and 575 nm. Cells stained with the green fluorescent dye YO-PRO-1 were
counted as apoptotic; necrotic cells stained with propidium iodide. The number of apoptotic
cells was divided by the total number of cells (minimum of 104 cells), giving the apoptotic
fraction. Data were analyzed using CellQuest software (Becton Dickinson). All observations
were reproduced at least thrice in independent experiments.
Fluorometric caspase 3 activity assay
Lysates were assayed for caspase 3 activity using the BD ApoAlert fluorometric Caspase Assay
Plate (BD Biosciences Clontech, Palo Alto, CA) in accordance with the manufacturer’s
instructions. Plates were read (excitation, 360 nm; emission, 480 nm) using a CytoFluor 4000
multiwell fluorescence plate reader (Applied Biosystems, Foster City, CA). A minimum of
three determinations was done for each sample.
Western blot analysis
Cells were washed with ice-cold PBS and whole cell extracts were prepared using cell lysis
buffer [20 mmol/L Tris (pH 7.5), 0.1% Triton X, 0.5% deoxycholate, 1 mmol/L phenyl-
methylsulfonyl fluoride, 10 µg/mL aprotinin, and 10 µg/mL leupeptin] and cleared by
centrifugation at 12,000 × g, 4°C. Total protein concentration was measured using the
bicinchoninic acid assay kit (Sigma, St Louis, MO) with bovine serum albumin as a standard.
Cell lysates containing 30 µg total protein were analyzed by immunoblotting. Anti-ILK, anti-
Akt, and anti-p-Akt (Ser473) antibodies were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-phospho-GSK-3α/β (Ser21/9) antibody was obtained from Cell Signaling
Technology (Beverly, MA). Anti-actin antibodies were obtained from LabVision (Freemont,
CA). Chemoluminescent detection (Upstate, Lake Placid, NY) was done in accordance with
the manufacturer’s instructions. The ILK signal was quantified using ImagePro Plus software
version 4.0 and normalized to that of actin.
Statistical analysis
Differences between groups were analyzed using Student’s t test, multifactorial ANOVA of
initial measurements and Mann Whitney U test, for nonparametric data, as appropriate, using
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Statistica 5.5 software (StatSoft, Inc., Tulsa, OK). In cases in which averages were normalized
to controls, the SDs of each nominator and denominator were taken into account in calculating
the final SD. P < 0.05 was considered statistically significant.
Results
Overexpression of active integrin-linked kinase increases pancreatic adenocarcinoma cell
gemcitabine chemoresistance
The gemcitabine IC50 values (concentration of gemcitabine required to inhibit cellular
proliferation by 50%) of the pancreatic adenocarcinoma cell lines PANC1, MIAPaCa2, and
Capan2 have been determined previously and we confirmed these results (20). The IC50 of
gemcitabine for PANC1, MIAPaCa2, and Capan2 are 50, 40, and 12 nmol/L, respectively.
Levels of ILK expression in PANC1, MIAPaCa2, and Capan2 cells were compared by Western
blotting (Fig. 1). PANC1 and MIAPaCa2, the most chemoresistant cell lines, exhibited greater
levels of ILK expression than Capan2, which has lower chemoresistance to gemcitabine. To
define the role of ILK in gemcitabine chemosensitivity, we established clones of Capan2 that
were stably transfected with a constitutively active ILK (S343D) expression construct.
Overexpression of ILK by two transfectant clones (Capan2-ILK1 and Capan2-ILK2) was
confirmed by Western blot analysis (Fig. 2A). The gemcitabine IC50 values for the parental
cell line (Capan2), empty vector transfectants (Capan2-pUSE), Capan2-ILK1, and Capan2-
ILK were quantified by MTT cytotoxicity assay. Whereas empty vector transfection had no
effect on gemcitabine IC50, overexpression of active ILK resulted in a significant increase in
chemoresistance to gemcitabine (Fig. 2B).
Integrin-linked kinase overexpression suppresses gemcitabine-induced caspase-mediated
apoptosis
Apoptosis was quantified by flow cytometric analysis. Following exposure of ILK transfectant
cells to 1 µmol/L gemcitabine for 24 hours, the apoptotic fraction of Capan2-ILK1 and Capan2-
ILK2 were, respectively, 40% and 46% less than that of Capan2-pUSE and Capan2 cells, which
showed no significant difference in their apoptotic response to gemcitabine (Fig. 3A).
Caspase 3 activities of cell lysates, obtained following exposure to 1 µmol/L gemcitabine for
24 hours, were quantified by fluorometric assay. Capan2-ILK1 and Capan2-ILK2 transfectants
exhibited a 45% and 55% lower level of caspase 3 activation than Capan2-pUSE transfectants,
respectively (Fig. 3B).
Integrin-linked kinase knockdown potentiates gemcitabine-induced cytotoxicity
PANC1 cells were chosen to study the effects of ILK knockdown as these cells inherently
express a relatively high level of ILK. ILK expression was suppressed by transfection of ILK-
specific siRNA. Forty-eight hours following transfection of siRNA, cells were subjected to
gemcitabine cytotoxicity assay as described previously. Continued suppression of ILK
expression of up to 75% was confirmed by Western blotting, 72 hours following siRNA
transfection (Fig. 4A). ILK knockdown resulted in a 51% decrease in the gemcitabine IC50, as
determined by MTT assay, relative to control siRNA transfectants (Fig. 4B). Both the apoptotic
fraction and caspase 3 activation induced by exposure to gemcitabine were significantly
increased following transfection of ILK-specific siRNA but not control siRNA (Fig. 4C and
D). Furthermore, when the apoptotic fraction was determined following exposure to
gemcitabine in the presence of the caspase inhibitor z-VAD-fmk, the increase in apoptotic
fraction induced by ILK knockdown was significantly reduced, signifying that increased
gemcitabine-induced apoptosis in cells exposed to ILK siRNA is caspase dependent.
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Integrin-linked kinase knockdown modulates Akt Ser473 and glycogen synthase kinase
phosphorylation
ILK facilitates the phosphorylation of Akt at Ser473, which is required for Akt activation
(21–23). In addition to modulating activity of Akt, ILK also induces phosphorylation of
downstream targets such as glycogen synthase kinase and myosin light chain (22). In view of
the important role of Akt in mediating pancreatic adenocarcinoma cellular resistance to
gemcitabine (14–16,24), we examined the effect of ILK knockdown on Akt Ser473
phosphorylation, as well as phosphorylation of its downstream target, GSK. We observed a
decrease in both Akt Ser473 phosphorylation (Fig. 5A) and phosphorylation of GSK (Fig. 5B)
in cells transfected with ILK siRNA, which is consistent with a model in which ILK facilitates
phosphorylation of Akt and GSK.
Activated Akt rescues cells from chemosensitization to gemcitabine induced by integrin-
linked kinase knockdown
Given the effects of ILK knockdown on Akt phosphorylation status, we sought to determine
the effects of concomitant overexpression of constitutively active Akt, and ILK knockdown,
on gemcitabine-induced cytotoxicity. Cotransfection of a constitutively active myristoylated
Akt expression construct at the time of ILK siRNA transfection was sufficient to maintain the
gemcitabine IC50 of PANC1 cells at levels significantly higher than those of cells in which
ILK knockdown was done in isolation (Fig. 6).
Discussion
Cellular adhesion to substrate is protective against a range of chemotherapeutic agents (7–
11). ILK plays a critical role in coupling extracellular signaling events to intracellular cell
survival pathways. In this study, we have shown for the first time that overexpression of active
ILK increases gemcitabine chemoresistance in pancreatic adenocarcinoma cells. This
chemoprotective effect occurs in association with suppression of caspase 3 activity.
Furthermore, posttranscriptional knockdown of ILK expression by RNAi enhances
gemcitabine-induced caspase 3–mediated apoptosis, decreases Akt Ser473 phosphorylation,
and suppresses levels of GSK phosphorylation. In addition to its recognized roles in transducing
signals resulting from growth factor receptor ligation and extracellular matrix interaction, ILK
can act as a determinant of pancreatic adenocarcinoma cellular resistance to gemcitabine.
Increased expression and activity of ILK protects epithelial cells from apoptotic events such
as anoikis, permitting anchorage-independent cell cycle progression and conferring greater
tumorigenic ability and cellular invasiveness (3,12,21,25). ILK interacts with β1 and β3
integrin subunits and is activated by contact with extracellular matrix components (1,21).
Overexpression of the ILK has been shown to modulate β-catenin subcellular localization and
function (3). ILK also facilitates phosphorylation of Akt at Ser473, which is a requirement for
Akt activation (21–23). Serine phosphorylation of Akt by ILK results in inhibitory
phosphorylation of the downstream target GSK (22), which is associated with greater resistance
to cellular insults such as exposure to ionizing irradiation (26,27). Akt has been recognized to
play an important role in pancreatic adenocarcinoma cellular chemoresistance (14–16) and the
ability of ILK knockdown to enhance gemcitabine-induced cytotoxicity is consistent with the
role of ILK as a regulator of Akt activity. We confirmed that Akt plays a significant role in the
changes in gemcitabine chemoresistance induced by ILK knockdown, as cotransfection of a
constitutively active myristoylated Akt expression construct was sufficient to preserve
gemcitabine chemoresistance significantly above that of cells in which ILK knockdown was
done in isolation. Whereas ILK-deficient chondrocytes have been shown to exhibit unaltered
Akt and GSK phosphorylation (28,29), others have shown Akt phosphorylation at Ser473 to be
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ILK dependent (30). Our results also suggest with an important role for ILK as a regulator of
Akt activity.
ILK is implicated in the genesis and progression of a variety of malignancies. However, ILK
expression has not been previously studied in pancreatic adenocarcinoma nor has its role in
cellular chemoresistance. ILK protein hyperexpression is an early event in colonic polyposis
(31) and carcinogenesis (32). ILK biochemical activity and protein expression is increased in
polyps from familial adenomatous polyposis patients. Sulindac and aspirin, two agents that
have been shown to have therapeutic and chemopreventive effects in colorectal carcinogenesis,
target ILK and ILK-mediated signaling events (31). Inhibition of ILK has been reported to
result in the transcriptional stimulation of E-cadherin expression and is correlated with
inhibition of transcription of snail, a repressor of E-cadherin gene expression (33). ILK also
plays a role in vascular endothelial growth factor–mediated tumor angiogenesis via protein
kinase B/Akt–dependent signaling (34).
Considerable evidence derived from work done in a variety of malignancies, including
pancreatic adenocarcinoma, indicates that Akt is a key regulator of cellular apoptosis (14–16,
18,35). Activated Akt protects cells from a variety of apoptotic stimuli, including exposure to
gemcitabine (14,15,18,35). The caspase cascade of proteolytic enzymes comprises initiator
and executioner elements. Following activation, these proteases degrade intracellular targets,
resulting in apoptotic cell death. Active Akt has been shown to phosphorylate initiator caspase
9 directly, preventing its activation (17). Inhibition of this initiator caspase may interfere with
apoptosome function and impair activation of effector caspase 3. Akt has also been reported
to inhibit caspases by post-translational modification of an as yet unidentified cytosolic factor
located downstream of cytochrome c release and upstream of caspase 9 activation (18). The
results of this study indicate that modulation of Akt activity through alteration of ILK
expression can influence pancreatic adenocarcinoma cellular gemcitabine chemoresistance.
In summary, our study is the first to characterize the role of ILK in mediating pancreatic
adenocarcinoma cellular chemoresistance. We have shown that whereas overexpression of ILK
protects cells against gemcitabine-induced apoptosis, posttranscriptional silencing of ILK
expression induces a significant increase in caspase-mediated apoptosis following exposure to
gemcitabine. Our findings suggest that strategies directed against ILK and its downstream
signaling targets may represent a novel approach to enhance the efficacy of gemcitabine in
pancreatic cancer.
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Fig. 1.
ILK expression among the pancreatic adenocarcinoma cell lines PANC1, MIAPaCa2, and
Capan2 was quantified by Western blot analysis. PANC1 and MIAPaCa2, which have the
greatest degree of gemcitabine chemoresistance (20), exhibited higher levels of ILK expression
than Capan2. Representative example with mean densitometric values from triplicate blots.*,
P < 0.05 versus Capan2 cells.
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Fig. 2.
A, stable overexpression of active ILK was confirmed by western blotting in Capan2-ILK1and
Capan2-ILK2 cells. Representative example with mean densitometric values from triplicate
blots.*, P < 0.05 versus Capan2-pUSE transfectants. B, gemcitabine IC50 was determined by
MTT cytotoxicity assay. Capan2-ILK1 and Capan2-ILK2 transfectants exhibited significantly
increased gemcitabine chemoresistance, relative to both parental cells (Capan2) and empty
vector transfectants (Capan2-pUSE).*, P < 0.05 versus Capan2-pUSE.
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Fig. 3.
A, apoptotic fraction of cells was determined by flow cytometric analysis of at least 10,000
cells following exposure to1 µmol/L gemcitabine for 24 hours. The apoptotic fractions of both
ILK transfectants were significantly lower than those of Capan2 and Capan2-pUSE. Columns,
mean values from triplicate experiments; bars,± SD.*, P < 0.05 versus Capan2-pUSE. B,
cellular caspase 3 activity following exposure to 1 µmol/L gemcitabine for 24 hours was
significantly lower in Capan2-ILK1 and Capan2-ILK2 transfectants. Columns, mean values
from triplicate experiments; bars, ±SD. *, P < 0.05 versus Capan2-pUSE.
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Fig. 4.
A, knockdown of ILK expression in PANC1 cells was confirmed by Western blot 48 hours
following transfection of ILK-specific but not control siRNA. Representative example with
mean densitometric values from triplicate blots. *, P < 0.05 versus control siRNA. B,
gemcitabine-induced cytotoxicity was significantly enhanced following ILK knockdown. *,
P < 0.05 versus control siRNA. Both the apoptotic fraction (C) and caspase 3 activation (D)
in response to gemcitabine were significantly increase by exposure to ILK-specific siRNA.
Apoptotic fraction of cells treated with ILK-specific siRNA was significantly reduced by
exposure to the caspase inhibitor z-VAD-fmk. Columns, mean values from triplicate
experiments; bars, ±SD. *, P < 0.05 versus control siRNA. †, P < 0.05 versus ILK siRNA.
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Fig. 5.
A, phosphospecific immunoblotting showed that knockdown of ILK expression suppressed
Akt Ser473 phosphorylation. B, inhibitory phosphorylation of glycogen synthase kinase (p-
GSK) was suppressed by ILK knockdown. Control siRNA had no effect on the phosphorylation
status of either Akt or GSK. Representative example with mean densitometric values from
triplicate blots. *, P < 0.05 versus control siRNA.
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Fig. 6.
Transfection of a constitutively active myristoylated Akt expression construct (myr-Akt)
induced significant recovery of the chemoresistant phenotype in PANC1 cells transfected with
ILK-specific siRNA. Gemcitabine IC50 values were quantified by MTT cytotoxicity assay.
Columns, mean values from triplicate experiments; bars, ±SD. *, P < 0.05 versus empty vector
(pUSE).
Duxbury et al. Page 14
Clin Cancer Res. Author manuscript; available in PMC 2009 August 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
